U.K.-based Oxford Micro Medical seeks to obtain $150,000 in outside capital, which it will use to further develop its NanoBreath device. The handheld device, which will integrate a mass spectrometry tool originally tailored for space exploration, is intended to offer a more cost-effective alternative to existing breath assays for detecting stomach cancer.

Related Summaries